Nationwide Children’s Hospital has licensed an experimental gene therapy for a fatal syndrome to a Cleveland biotech startup that’s aiming to start clinical trials next year.
Abeona Therapeutics LLC said in a release it is raising funds this month toward starting Phase 1 and 2 trials, which test safety and get preliminary data on effectiveness of a drug on the way toward U.S. Food and Drug Administration approval. (Actually they buried the lead in a release about an award.)
Such efforts take…
via Columbus Business News – Local Columbus News | Business First of Columbus
Nationwide Children’s spinoff starts approval process for gene therapy for rare fatal syndrome